Literature DB >> 15735028

PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma.

Yuan Rong1, Dawn E Post, Russell O Pieper, Donald L Durden, Erwin G Van Meir, Daniel J Brat.   

Abstract

We have previously proposed that intravascular thrombosis and subsequent vasoocclusion contribute to the development of pseudopalisading necrosis, a pathologic hallmark that distinguishes glioblastoma (WHO grade 4) from lower grade astrocytomas. To better understand the potential prothrombotic mechanisms underlying the formation of these structures that drive tumor angiogenesis, we investigated tissue factor (TF), a potent procoagulant protein known to be overexpressed in astrocytomas. We hypothesized that PTEN loss and tumor hypoxia, which characterize glioblastoma but not lower grade astrocytomas, could up-regulate TF expression and cause intravascular thrombotic occlusion. We examined the effect of PTEN restoration and hypoxia on TF expression and plasma coagulation using a human glioma cell line containing an inducible wt-PTEN cDNA. Cell exposure to hypoxia (1% O(2)) markedly increased TF expression, whereas restoration of wt-PTEN caused decreased cellular TF. The latter effect was at least partially dependent on PTEN's protein phosphatase activity. Hypoxic cells accelerated plasma clotting in tilt tube assays and this effect was prevented by both inhibitory antibodies to TF and plasma lacking factor VII, implicating TF-dependent mechanisms. To further examine the genetic events leading to TF up-regulation during progression of astrocytomas, we investigated its expression in a series of human astrocytes sequentially infected with E6/E7/human telomerase, Ras, and Akt. Cells transformed with Akt showed the greatest incremental increase in hypoxia-induced TF expression and secretion. Together, our results show that PTEN loss and hypoxia up-regulate TF expression and promote plasma clotting by glioma cells, suggesting that these mechanisms may underlie intravascular thrombosis and pseudopalisading necrosis in glioblastoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15735028     DOI: 10.1158/0008-5472.CAN-04-3376

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  63 in total

Review 1.  Protease-activated receptor 2 signaling in inflammation.

Authors:  Andrea S Rothmeier; Wolfram Ruf
Journal:  Semin Immunopathol       Date:  2011-10-06       Impact factor: 9.623

2.  Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles.

Authors:  Nadim Tawil; Rayhaan Bassawon; Brian Meehan; Ali Nehme; Laura Montermini; Tenzin Gayden; Nicolas De Jay; Cristiana Spinelli; Shilpa Chennakrishnaiah; Dongsic Choi; Lata Adnani; Michele Zeinieh; Nada Jabado; Claudia L Kleinman; Michael Witcher; Yasser Riazalhosseini; Nigel S Key; David Schiff; Steven P Grover; Nigel Mackman; Charles P Couturier; Kevin Petrecca; Mario L Suvà; Anoop Patel; Itay Tirosh; Hamed Najafabadi; Janusz Rak
Journal:  Blood Adv       Date:  2021-03-23

3.  Tissue Factor Regulation by miR-520g in Primitive Neuronal Brain Tumor Cells: A Possible Link between Oncomirs and the Vascular Tumor Microenvironment.

Authors:  Esterina D'Asti; Annie Huang; Marcel Kool; Brian Meehan; Jennifer A Chan; Nada Jabado; Andrey Korshunov; Stefan M Pfister; Janusz Rak
Journal:  Am J Pathol       Date:  2015-12-12       Impact factor: 4.307

4.  Differential sensitivity of human glioblastoma LN18 (PTEN-positive) and A172 (PTEN-negative) cells to Taxol for apoptosis.

Authors:  Ran Zhang; Naren L Banik; Swapan K Ray
Journal:  Brain Res       Date:  2008-09-04       Impact factor: 3.252

5.  Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initiation and angiogenesis.

Authors:  Chloe C Milsom; Joanne L Yu; Nigel Mackman; Johann Micallef; G Mark Anderson; Abhijit Guha; Janusz W Rak
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

6.  Tissue factor expression provokes escape from tumor dormancy and leads to genomic alterations.

Authors:  Nathalie Magnus; Delphine Garnier; Brian Meehan; Serge McGraw; Tae Hoon Lee; Maxime Caron; Guillaume Bourque; Chloe Milsom; Nada Jabado; Jacquetta Trasler; Rafal Pawlinski; Nigel Mackman; Janusz Rak
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-11       Impact factor: 11.205

7.  Thromboembolic disease in patients with high-grade glioma.

Authors:  James R Perry
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

Review 8.  Breast cancer phenotypes regulated by tissue factor-factor VII pathway: Possible therapeutic targets.

Authors:  Shiro Koizume; Yohei Miyagi
Journal:  World J Clin Oncol       Date:  2014-12-10

9.  Mutant IDH1 and thrombosis in gliomas.

Authors:  Dusten Unruh; Steven R Schwarze; Laith Khoury; Cheddhi Thomas; Meijing Wu; Li Chen; Rui Chen; Yinxing Liu; Margaret A Schwartz; Christina Amidei; Priya Kumthekar; Carolina G Benjamin; Kristine Song; Caleb Dawson; Joanne M Rispoli; Girish Fatterpekar; John G Golfinos; Douglas Kondziolka; Matthias Karajannis; Donato Pacione; David Zagzag; Thomas McIntyre; Matija Snuderl; Craig Horbinski
Journal:  Acta Neuropathol       Date:  2016-09-23       Impact factor: 17.088

10.  Identification of a novel small molecule HIF-1alpha translation inhibitor.

Authors:  Takuhito Narita; Shaoman Yin; Christine F Gelin; Carlos S Moreno; Manuel Yepes; K C Nicolaou; Erwin G Van Meir
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.